Clinical trial data reveals what controls the staying power of T cells, affecting immunotherapy responses. St. Jude scientists' findings were published in Cell Reports.
St. Jude scientists map nutrient-dependent signaling in T cells, offering possible new drug targets for treating infectious diseases, cancer and immune-mediated disorders.
Findings from St. Jude Children’s Research Hospital show how epigenetic regulation by the enzyme DNMT3A controls T-cell exhaustion providing a target for improving CAR T–cell immunotherapy.
The fourteen scientists are among the most highly cited investigators in the world during the past decade, reflecting the international reach of St. Jude research.
St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.
Following FDA authorization of the COVID-19 vaccine for children ages 5 to 11, St. Jude releases a free coloring book that educates children on vaccines.
Findings from St. Jude Children’s Research Hospital show that cell-free DNA in cerebrospinal fluid can be used to detect measurable residual disease and identify patients at risk of relapse.
St. Jude scientists developed a test to look for signals that identify the presence of cell-free DNA from medulloblastoma.
Scientists at St. Jude and Dana-Farber Cancer Institute learned how retinoic acid changes tumor cells in children with high-risk neuroblastoma.
Results offer clues for enhancing interferon effectiveness in cancer treatment.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.